OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Medical Virology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines	622
Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein	414
Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysis	385
The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant	355
Vaccine hesitancy: Beliefs and barriers associated with COVID‐19 vaccination among Egyptian medical students	303
Role of Toll‐like receptors in the pathogenesis of COVID‐19	274
Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective	224
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review	218
OMICRON (B.1.1.529): A new SARS‐CoV‐2 variant of concern mounting worldwide fear	205
A brief review of influenza virus infection	204
Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A preliminary pooled data analysis and literature review	185
Sequence analysis of the emerging SARS‐CoV‐2 variant Omicron in South Africa	182
Chronic COVID syndrome: Need for an appropriate medical terminology for long‐COVID and COVID long‐haulers	169
A large‐scale meta‐analytic atlas of mental health problems prevalence during the COVID‐19 early pandemic	168
SARS‐CoV‐2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG‐I/MDA‐5–MAVS, TLR3–TRIF, and cGAS–STING signaling pathways	167
Relative instantaneous reproduction number of Omicron SARS‐CoV‐2 variant with respect to the Delta variant in Denmark	165
Omicron variant genome evolution and phylogenetics	153
Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert!	153
Droplet digital PCR of viral ‎DNA/RNA, current progress, challenges, and future perspectives	133
Omicron (BA.1) and sub‐variants (BA.1.1, BA.2, and BA.3) of SARS‐CoV‐2 spike infectivity and pathogenicity: A comparative sequence and structural‐based computational assessment	130
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Spike mutation T478K	129
Long COVID syndrome‐associated brain fog	126
Emergence of Omicron third lineage BA.3 and its importance	123
Autoimmune complications of COVID‐19	113
Safety of COVID‐19 vaccines	112

Obesity aggravates COVID‐19: An updated systematic review and meta‐analysis	111
Risk factors prediction, clinical outcomes, and mortality in COVID‐19 patients	103
Role of toll‐like receptors in modulation of cytokine storm signaling in SARS‐CoV‐2‐induced COVID‐19	102
Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID‐19 pandemic	102
Non‐life‐threatening adverse effects with COVID‐19 mRNA‐1273 vaccine: A randomized, cross‐sectional study on healthcare workers with detailed self‐reported symptoms	102
Anemia is associated with severe illness in COVID‐19: A retrospective cohort study	97
Evolutionary dynamics of SARS‐CoV‐2 nucleocapsid protein and its consequences	96
Genomic annotation and molecular evolution of monkeypox virus outbreak in 2022	95
Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review	95
Defining IL‐6 levels in healthy individuals: A meta‐analysis	94
SARS‐CoV‐2 variants and vulnerability at the global level	91
Post‐COVID syndrome: A single‐center questionnaire study on 1007 participants recovered from COVID‐19	90
COVID‐19 vaccinations: The unknowns, challenges, and hopes	90
The inflammatory markers of multisystem inflammatory syndrome in children (MIS‐C) and adolescents associated with COVID‐19: A meta‐analysis	90
Re‐emerging human monkeypox: A major public‐health debacle	90
Evaluation of seven commercial RT‐PCR kits for COVID‐19 testing in pooled clinical specimens	89
Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA and neutralization activity	88
The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity	88
The global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: A systematic review and meta‐analysis	88
The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape	83
Cycle threshold values in RT‐PCR to determine dynamics of SARS‐CoV‐2 viral load: An approach to reduce the isolation period for COVID‐19 patients	82
Effects of SARS‐CoV‐2 mutations on protein structures and intraviral protein–protein interactions	81
COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts	80
Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID‐19: A systematic review and meta‐analysis	79
SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?	76
Impact of COVID‐19 in patients with concurrent co‐infections: A systematic review and meta‐analyses	76
Kidney involvement in COVID‐19 and its treatments	73
Vitamin D deficiency is associated with COVID‐19 positivity and severity of the disease	72
Herpes zoster emergence following mRNA COVID‐19 vaccine	72
Coronapp: A web application to annotate and monitor SARS‐CoV‐2 mutations	71
Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study	71
In silico analyses on the comparative sensing of SARS‐CoV‐2 mRNA by the intracellular TLRs of humans	71
Post‐COVID syndrome symptoms, functional disability, and clinical severity phenotypes in hospitalized and nonhospitalized individuals: A cross‐sectional evaluation from a community COVID rehabilitatio	70
Differences in incidence and fatality of COVID‐19 by SARS‐CoV‐2 Omicron variant versus Delta variant in relation to vaccine coverage: A world‐wide review	69
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates	68
Molecular evolutionary characteristics of SARS‐CoV‐2 emerging in the United States	68
Placental SARS‐CoV‐2 in a pregnant woman with mild COVID‐19 disease	68
Monkeypox: A potential global threat?	67
Proportion of asymptomatic infection and nonsevere disease caused by SARS‐CoV‐2 Omicron variant: A systematic review and analysis	67
Characteristics of the first 1119 SARS‐CoV‐2 Omicron variant cases, in Marseille, France, November−December 2021	65
Possible vertical transmission and antibodies against SARS‐CoV‐2 among infants born to mothers with COVID‐19: A living systematic review	64
The role of type I interferon in the treatment of COVID‐19	64
Understanding the pathophysiological changes via untargeted metabolomics in COVID‐19 patients	64
Risk factors for bacterial infections in patients with moderate to severe COVID‐19: A case‐control study	63
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID‐19	63
The COVID‐19 Yorkshire Rehabilitation Scale (C19‐YRS): Application and psychometric analysis in a post‐COVID‐19 syndrome cohort	63
Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID‐19: A case study	62
Safety and effectiveness of SARS‐CoV‐2 vaccines: A systematic review and meta‐analysis	62
Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy	61
mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses	61

SARS‐CoV‐2‐specific virulence factors in COVID‐19	61
SARS‐CoV‐2 antibodies: IgA correlates with severity of disease in early COVID‐19 infection	61
The puzzling mutational landscape of the SARS‐2‐variant Omicron	61
Mutational and phylogenetic analyses of the two lineages of the Omicron variant	61
Antibody response to SARS‐CoV‐2 vaccination is extremely vivacious in subjects with previous SARS‐CoV‐2 infection	61
In the age of Omicron variant: Paxlovid raises new hopes of COVID‐19 recovery	61
Omicron (B.1.1.529 variant of SARS‐CoV‐2); an emerging threat: Current global scenario	60
Persistent circulation of soluble and extracellular vesicle‐linked Spike protein in individuals with postacute sequelae of COVID‐19	60
Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers	60
Emerging evidence on Omicron (B.1.1.529) SARS‐CoV‐2 variant	58
Use of chlorhexidine to eradicate oropharyngeal SARS‐CoV‐2 in COVID‐19 patients	58
Twin combination of Omicron and Delta variants triggering a tsunami wave of ever high surges in COVID‐19 cases: A challenging global threat with a special focus on the Indian subcontinent	57
The use of renin–angiotensin–aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID‐19 patients: A systematic review and meta‐analysis	55
Attaching a stigma to the LGBTQI+ community should be avoided during the monkeypox epidemic	55
Fetal and placental infection with SARS‐CoV‐2 in early pregnancy	55
SARS‐CoV‐2 ORF10 antagonizes STING‐dependent interferon activation and autophagy	55
A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS‐CoV‐2 vaccine	55
The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta‐plus variants: A hint to higher transmissibility?	54
Association between COVID‐19 and telomere length: A bidirectional Mendelian randomization study	54
Gastroenterology manifestations and COVID‐19 outcomes: A meta‐analysis of 25,252 cohorts among the first and second waves	54
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review	53
Host factors and vaccine efficacy: Implications for COVID‐19 vaccines	53
Soluble angiotensin‐converting enzyme 2 is transiently elevated in COVID‐19 and correlates with specific inflammatory and endothelial markers	53
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis	53
Viral coinfections in COVID‐19	53
SARS‐CoV‐2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two‐dose CoronaVac vaccine regimen	53
Coronavirus genomic nsp14‐ExoN, structure, role, mechanism, and potential application as a drug target	53
COVID‐19 related fatigue: Which role for rehabilitation in post‐COVID‐19 patients? A case series	51
Evaluation of antibody response after COVID‐19 vaccination of healthcare workers	51
Detection of SARS‐CoV‐2 Omicron (B.1.1.529) variant has created panic among the people across the world: What should we do right now?	51
Rhinovirus spread in children during the COVID‐19 pandemic despite social restrictions—A nationwide register study in Finland	51
Co‐infection of influenza A virus and SARS‐CoV‐2: A retrospective cohort study	51
Apoptosis‐induced T‐cell lymphopenia is related to COVID‐19 severity	51
Detection of highly muted coronavirus variant Omicron (B.1.1.529) is triggering the alarm for South Asian countries: Associated risk factors and preventive actions	50
Antibody response patterns in COVID‐19 patients with different levels of disease severity in Japan	50
SARS‐CoV‐2 infection affects the lower urinary tract and male genital system: A systematic review	48
Performance of a rapid antigen test in the diagnosis of SARS‐CoV‐2 infection	48
Association between red blood cell distribution width and mortality and severity among patients with COVID‐19: A systematic review and meta‐analysis	48
Role of platelet‐to‐lymphocyte count ratio (PLR), as a prognostic indicator in COVID‐19: A systematic review and meta‐analysis	47
Evaluation of the prognostic role of NLR, LMR, PLR, and LCR ratio in COVID‐19 patients	47
Melatonin effects on sleep quality and outcomes of COVID‐19 patients: An open‐label, randomized, controlled trial	46
Questions concerning the proximal origin of SARS‐CoV‐2	46
Stability and transmissibility of SARS‐CoV‐2 in the environment	46
Effect of mutation and vaccination on spread, severity, and mortality of COVID‐19 disease	46
The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials	46
Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19	46
Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection	46
Effect of using a structured pacing protocol on post‐exertional symptom exacerbation and health status in a longitudinal cohort with the post‐COVID‐19 syndrome	45
COVID‐19‐associated Guillain‐Barre syndrome: Postinfectious alone or neuroinvasive too?	45
Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS‐COV‐2 lineage in Peru despite circulation of variants of concern	45
A cluster of the new SARS‐CoV‐2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine	45
Vaccination versus infection with SARS‐CoV‐2: Establishment of a high avidity IgG response versus incomplete avidity maturation	45
A pilot double‐blind safety and feasibility randomized controlled trial of high‐dose intravenous zinc in hospitalized COVID‐19 patients	45
Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects	45
The other side of COVID‐19 pandemic: Effects on male fertility	44
Acceptance of COVID‐19 booster vaccination based on the protection motivation theory: A cross‐sectional study in China	44
The SARS‐CoV‐2 omicron wave is indicating the end of the pandemic phase but the COVID‐19 will continue	44
Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID	44
Prevalence and factors related to COVID‐19 vaccine hesitancy and unwillingness in Canada: A systematic review and meta‐analysis	44
Culture and identification of a “Deltamicron” SARS‐CoV‐2 in a three cases cluster in southern France	43
A systematic review and meta‐analysis of long‐term sequelae of COVID‐19 2‐year after SARS‐CoV‐2 infection: A call to action for neurological, physical, and psychological sciences	43
Causal effect of COVID‐19 on Alzheimer's disease: A Mendelian randomization study	43
Characterization of antibody responses to SARS‐CoV‐2 in convalescent COVID‐19 patients	42
Safety and efficacy of COVID‐19 vaccines in children and adolescents: A systematic review of randomized controlled trials	42
Viral proteins recognized by different TLRs	41
Roles of the polybasic furin cleavage site of spike protein in SARS‐CoV‐2 replication, pathogenesis, and host immune responses and vaccination	41
Toward an understanding of regulatory T cells in COVID‐19: A systematic review	41
The mechanism of multiple organ dysfunction syndrome in patients with COVID‐19	41
Targeting SARS‐CoV‐2 viral proteases as a therapeutic strategy to treat COVID‐19	41
The recombinant variants of SARS‐CoV‐2: Concerns continues amid COVID‐19 pandemic	41
Reinfection of COVID‐19 after 3 months with a distinct and more aggressive clinical presentation: Case report	40
Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post‐acute sequelae of COVID‐19	40
Anti‐SARS‐CoV‐2 IgG levels in relation to disease severity of COVID‐19	40
Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVID‐19	40
Global case fatality rate from COVID‐19 has decreased by 96.8% during 2.5 years of the pandemic	40
Quantitative assessment of SARS‐CoV‐2 RNAemia and outcome in patients with coronavirus disease 2019	39
Clinical trials on the pharmacological treatment of long COVID: A systematic review	39
Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or obesity	39
The changing pattern of common respiratory and enteric viruses among outpatient children in Shanghai, China: Two years of the COVID‐19 pandemic	39
Mpox diagnostics: Review of current and emerging technologies	38

mRNA vaccines: The future of prevention of viral infections?	38
Bidirectional causal associations between type 2 diabetes and COVID‐19	38
The SARS‐CoV‐2 Omicron (B.1.1.529) variant and effectiveness of existing vaccines: What we know so far	38
Comparative safety of mRNA COVID‐19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database	38
Vitamin D and COVID‐19: Role of ACE2, age, gender, and ethnicity	38
The modified COVID‐19 Yorkshire Rehabilitation Scale (C19‐YRSm) patient‐reported outcome measure for Long Covid or Post‐COVID‐19 syndrome	38
Omicron BA.2 lineage spreads in clusters and is concentrated in Denmark	37
Novel statistics predict the COVID‐19 pandemic could terminate in 2022	37
Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID‐2019) in 23 countries	37
COVID‐19 encephalopathy: Clinical and neurobiological features	37
Adverse events following immunization of COVID‐19 (Covaxin) vaccine at a tertiary care center of India	37
COVID‐19 and Zika: An emerging dilemma for Brazil	37
Microbiota and HPV: The role of viral infection on vaginal microbiota	37
Long COVID following Omicron wave in Eastern India—A retrospective cohort study	37
Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges	37
Dynamics of antibody response to CoronaVac vaccine	37
Molecular biology of the SARs‐CoV‐2 spike protein: A review of current knowledge	37
N protein‐based ultrasensitive SARS‐CoV‐2 antibody detection in seconds via 3D nanoprinted, microarchitected array electrodes	36
Persistence of neutrophil extracellular traps and anticardiolipin auto‐antibodies in post‐acute phase COVID‐19 patients	36
Mucormycosis or black fungus infection is a new scare in South Asian countries during the COVID‐19 pandemic: Associated risk factors and preventive measures	36
Respiratory virus circulation in children after relaxation of COVID‐19 restrictions in fall 2021—A nationwide register study in Finland	36
Prevalence and correlates of COVID‐19 vaccine hesitancy in the general public in Iraqi Kurdistan: A cross‐sectional study	36
Omicron: Call for updated vaccines	36
Three salvianolic acids inhibit 2019‐nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2	35
Paracetamol in the home treatment of early COVID‐19 symptoms: A possible foe rather than a friend for elderly patients?	35
The association between the level of serum 25(OH) vitamin D, obesity, and underlying diseases with the risk of developing COVID‐19 infection: A case–control study of hospitalized patients in Tehran, I	35
Molecular evolution of SARS‐CoV‐2 from December 2019 to August 2022	35
Association of GSTM1 and GSTT1 gene polymorphisms with COVID‐19 susceptibility and its outcome	35
Total antioxidant capacity as a marker of severity of COVID‐19 infection: Possible prognostic and therapeutic clinical application	35
Palmitoylation of SARS‐CoV‐2 S protein is critical for S‐mediated syncytia formation and virus entry	35
Evaluation of the relationship between serum levels of zinc, vitamin B12, vitamin D, and clinical outcomes in patients with COVID‐19	34
Correlation between vaccine coverage and the COVID‐19 pandemic throughout the world: Based on real‐world data	34
A systematic review of acute telogen effluvium, a harrowing post‐COVID‐19 manifestation	34
Symptomatic reinfection of SARS‐CoV‐2 with spike protein variant N440K associated with immune escape	34
Fewer non‐COVID‐19 respiratory tract infections and gastrointestinal infections during the COVID‐19 pandemic	34
Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus‐2 Omicron Variant of Concern	34
Evaluation of maternal serum afamin and vitamin E levels in pregnant women with COVID‐19 and its association with composite adverse perinatal outcomes	33
Monkeypox viral detection in semen specimens of confirmed cases: A systematic review and meta‐analysis	33
SARS‐CoV‐2 ORF3a inhibits cGAS‐STING‐mediated autophagy flux and antiviral function	33
Gold nanoparticle conjugate‐based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS‐CoV‐2 in clinical samples using a smartphone‐based application	33
Vertical transmission of SARS‐CoV‐2: A prospective cross‐sectional study from a tertiary center	32
Transmission of monkeypox/mpox virus: A narrative review of environmental, viral, host, and population factors in relation to the 2022 international outbreak	32
Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study	32
The effectiveness of inactivated SARS‐CoV‐2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older	32
The comprehensive clinic, laboratory, and instrumental evaluation of children with COVID‐19: A 6‐months prospective study	32
Emerging SARS‐CoV‐2 variants can potentially break set epidemiological barriers in COVID‐19	32
Association between the HLA genotype and the severity of COVID‐19 infection among South Asians	32
Estimation of undetected symptomatic and asymptomatic cases of COVID‐19 infection and prediction of its spread in the USA	31
CRISPR–Cas12‐based field‐deployable system for rapid detection of synthetic DNA sequence of the monkeypox virus genome	31
SARS‐CoV‐2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID‐19	31
Diagnostic accuracy of the Cepheid Xpert Xpress and the Abbott ID NOW assay for rapid detection of SARS‐CoV‐2: A systematic review and meta‐analysis	31
The willingness of Chinese healthcare workers to receive monkeypox vaccine and its independent predictors: A cross‐sectional survey	31
Bibliometric analysis of global research trends on monkeypox: Are we ready to face this challenge?	31
Prevotella as the hub of the cervicovaginal microbiota affects the occurrence of persistent human papillomavirus infection and cervical lesions in women of childbearing age via host NF‐κB	31
Human monkeypox outbreak in 2022	31
High proportion of low cycle threshold value as an early indicator of COVID‐19 surge	31
The emergence of Omicron lineages BA.4 and BA.5, and the global spreading trend	31
Persistence of symptoms after improvement of acute COVID19 infection, a longitudinal study	31
Can COVID‐19 cause atypical forms of pityriasis rosea refractory to conventional therapies?	31
Co‐infection of malaria and early clearance of SARS‐CoV‐2 in healthcare workers	30
Immunogenicity and safety of the BNT162b2 COVID‐19 mRNA vaccine in PLWH: A monocentric study in Bari, Italy	30
SARS‐CoV‐2 prevalence and maternal‐perinatal outcomes among pregnant women admitted for delivery: Experience from COVID‐19‐dedicated maternity hospital in Jammu, Jammu and Kashmir (India)	30
Mutations in SARS‐CoV‐2 nsp7 and nsp8 proteins and their predicted impact on replication/transcription complex structure	30
Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign	30
RT‐PCR/MALDI‐TOF mass spectrometry‐based detection of SARS‐CoV‐2 in saliva specimens	30
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease‐2019 (COVID‐19): A systematic review and meta‐analysis	30
AstraZeneca (AZD1222) COVID‐19 vaccine‐associated adverse drug event: A case report	30
Omicron and S‐gene target failure cases in the highest COVID‐19 case rate region in Canada—December 2021	30
Vaccine design based on 16 epitopes of SARS‐CoV‐2 spike protein	30
COVID‐19 immunopathology: From acute diseases to chronic sequelae	30
Decreased in‐hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID‐19	30
Dengue and COVID‐19: A double burden to Brazil	30
Evaluation of serum IgM and IgG antibodies in COVID‐19 patients by enzyme linked immunosorbent assay	30
Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients	30
Prevalence and genotype distribution of high‐risk HPV infection among women in Beijing, China	30
In vitro activity of itraconazole against SARS‐CoV‐2	30
Guidelines on newly identified limitations of diagnostic tools for COVID‐19 and consequences	29
Will the emergent SARS‐CoV2 B.1.1.7 lineage affect molecular diagnosis of COVID‐19?	29
Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies	29
Targeting the viral‐entry facilitators of SARS‐CoV‐2 as a therapeutic strategy in COVID‐19	29
The variants of SARS‐CoV‐2 and the challenges of vaccines	29
Axonal Guillain‐Barre syndrome associated with SARS‐CoV‐2 infection in a child	29
SARS‐CoV‐2 pseudovirus infectivity and expression of viral entry‐related factors ACE2, TMPRSS2, Kim‐1, and NRP‐1 in human cells from the respiratory, urinary, digestive, reproductive, and immune syste	29
An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey	29
Fungemia in COVID‐19 ICU patients, a single medical center experience	29
The global case fatality rate of coronavirus disease 2019 by continents and national income: A meta‐analysis	29
Third dose of SARS‐CoV‐2 vaccine: A systematic review of 30 published studies	29
Epidemiological changes of common respiratory viruses in children during the COVID‐19 pandemic	29
Impact of COVID‐19 on the mental health in a cohort of Italian rehabilitation healthcare workers	29
Prognostic roles of KL‐6 in disease severity and lung injury in COVID‐19 patients: A longitudinal retrospective analysis	28
Saliva samples for detection of SARS‐CoV‐2 in mildly symptomatic and asymptomatic patients	28
High value of mid‐regional proadrenomedullin in COVID‐19: A marker of widespread endothelial damage, disease severity, and mortality	28
Impact of social distancing on incidence of vaccine‐preventable diseases, South Korea	28
A phenome‐wide investigation of risk factors for severe COVID‐19	28
Pathogenesis‐directed therapy of 2019 novel coronavirus disease	28